Jobs / United States / Natera INC
Area Medical Director - Oncology
Natera INC · 🇺🇸 US Remote · Remote
Sponsorship verdict
Sponsorship possible
One solid signal, not two — worth applying, and worth asking about sponsorship early.
- Employer is on a government sponsor recordThe US Department of Labor certified 48 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 12 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
- The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
- No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.
- What Natera INC paid sponsored hires in similar roles1 certified filing for “Clinical Lab Scientist I” (Medical and Clinical Laboratory Technologists) in CA: $86k–$86k, median $86k. Most were filed at wage level III (100%) — 3 lottery entries, ≈46% projected selection odds for cap-subject employers. Source: US Department of Labor LCA disclosure data (Oct 2025 – Jun 2026).
- Confirmed live todayWhen a source last listed this job as open.
US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).
A verdict summarises public evidence; it is not legal advice and never a guarantee — the employer and the immigration authority decide. Sign in to factor in where you can already work.
Or apply yourself on the official page →
Sponsor Radar — Natera INC
The US Department of Labor certified 48 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 12 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
Past sponsorship or register membership never guarantees sponsorship for this vacancy or for you. Full Sponsor Radar for Natera INC →
About the role
POSITION SUMMARY The Area Medical Director (AMD) is a senior physician leader embedded within a defined geography (Northeast, East, Central, or West) to serve as Natera's primary MD-to-MD clinical presence across the community oncology market. This role addresses the intersection of medical affairs, field execution, and scientific credibility — driving engagement with community oncologists, KOLs, and cross-functional field teams to accelerate appropriate utilization of Natera's oncology portfolio, including Signatera and Altera. The AMD owns regional medical strategy, leads cross-functional field partnerships, and operates with high autonomy to define and execute area priorities. The AMD functions without a defined playbook, translates business strategy into field-level action, and surfaces clinical intelligence that informs both commercial execution and development priorities. This is a 50% field-based role. PRIMARY RESPONSIBILITIES MD-Level Field Engagement ● Execute 12–18 MD-level engagements per quarter across defined geography, with at least 50% concentrated in top strategic community accounts. ● Maintain field presence of at least 4 ride days per month, prioritizing and overseeing area high-value and "platinum" accounts, including lost/down account retrieval. Responsible/accountable for oversight and coordination with these accounts with Associate AMD. ● Establish and maintain contact with the medical lead in the top 20 area accounts; engage 100% of flagged accounts within 10 business days. Cross-Functional Medical Leadership ● Serve as the primary MD triage point for escalated area medical inquiries, acknowledging at least 90% within 48 hours with 100% closed-loop documentation in Salesforce. ● Partner with MSL managers, Area Sales Directors, and Area Marketing Directors through structured bi-weekly and monthly cadences to align scientific messaging and commercial strategy. ● Participate in at least 75% of high-priority account strategy reviews and area/regional planning sessions; co-own quarterly business reviews with MSL leadership. • Proficiency with and current understanding of Natera’s evidence generation portfolio and ability to speak to/escalate questions or issues coming from area accounts. Scientific Communication and Education ● Host, present, or observe at least 12 regional educational programs per quarter targeting high-impact community accounts. ● Lead development of at least one educational initiative per cycle (physician-facing, patient-facing, or via webinar/podcast); complete annual recurrent speaker training. ● Ensure consistent, compliant scientific positioning across field activities; document objection-handling themes and manage escalation to histology-specific Medical Directors where appropriate. Clinical Development Contribution ● Identify and document field-driven evidence generation opportunities; surface at least one histology-specific clinical trial concept per year in collaboration with the CMO and histology Medical Director teams. ● Generate at least 3 actionable regional insights per quarter in quarterly written reports submitted prior to manager review. ● Identify at least 3 qualified KOL collaboration leads per quarter, including IST/RWE prospects, documented in Salesforce. Performs other duties as assigned. QUALIFICATIONS Required: ● M.D. or D.O. with board certification in oncology, hematology, or a directly related clinical specialty. ● Minimum 5–8 years of related clinical or medical affairs experience following board certification (HM5 level; equivalent field experience accepted). ● Demonstrated proficiency across multiple tumor histologies and working knowledge of the molecular residual disease (MRD) diagnostic landscape. ● Experience in a field-based medical